预约演示

FibroGen and Fortis sign exclusive licence deal for mCRPC drug candidate

2023-05-09

临床1期引进/卖出抗体药物偶联物并购

FOR46 is being developed as a potential treatment for metastatic castration-resistant prostate cancer. Credit: Nephron/commons.wikimedia.org

FOR46Gen has signed an exclusive licence agreement witmetastatic castration-resistant prostate cancerug conjugate (ADC) that targets a new epitope on CD46, a protein-coding gene.

FibroGen currently being investigated in a Phase I trialFortis Therapeuticsatment for metastatic castration-resistant prostate cancer (mCRPC).CD46

FOR46mended Reportsmetastatic castration-resistant prostate cancer (mCRPC)

ReportsLOA and PTSR Model - (Metyrapone + Oxazepam) in Substance (Drug) Abuse GlobalData

ReportsLOA and PTSR Model - Esmethadone Hydrochloride in Substance (Drug) Abuse GlobalData

View allMetyrapone Oxazepam

The trial is also studying the capability of FOR46 for use in other CD46-expressing cancers.

The new deal, which does notEsmethadoney initial consideration, will see FibroGen conducting and financing new research, development and production of FOR46 and PET46.

Throughout the deal’s four-year evaluation period, FibroGen has an option to buy Fortis Therapeutics for $80m.

Fortis can also receive up to $200m in total FOR46e basis of multiplCD46-expressing cancers CD46-expressingprovals.

Under the clinical development strategy, FibroGen will continue the work FibroGens Therapeutics to develop a PET-based biomarker using a radiolabeled version of the targeting antibody (PET46) for selecting patients.

FibroGen CEO Enrique Conterno stated: “The agreemenFibroGenortis Therapeutics bolFortis Therapeuticsinical pipeline in a capital-efficient manner, providing a product candidate with the potential to address a significant unmet medical need in oncology.

Fortis is a natural fit with our research and development capabilities and expertise.

“The flexibility of the agreement gives uFibroGenportunity to clinically devFortis Therapeuticsimately acquire it as a Phase III-ready asset, potentially delivering a therapy that may transform the treatment of patients with mCRPC and other CD46-expressing cancers.”

FibroGen May 2023, FibroGen announced that it would receivFortis Therapeuticsive term lFibroGenlity from funds managed by Morgan Stanley Tactical Value (MSTV) to accelerate the commercialisation of pamrevlumab.oncology

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构